Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Analyst consensus is “Moderate Buy”: Seven of eight analysts rate Corbus Pharmaceuticals a buy, while one rates it a sell. The average 12-month price target is $39.57.
• Insiders have been selling shares: The CEO and CFO sold a combined 29,000 shares at $10.08 each, while insiders sold 31,000 shares worth about $308,000 over the past 90 days.
• The stock faces significant financial pressure: CRBP opened at $4.05, near its 52-week low of $3.93, and its latest quarterly loss of $1.81 per share was worse than analysts’ expected loss of $1.26.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $39.57.

A number of equities research analysts have recently weighed in on CRBP shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research note on Thursday, October 15th. Mizuho set a $33.00 price target on Corbus Pharmaceuticals in a research note on Thursday, August 13th. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday, September 14th. Wall Street Zen downgraded Corbus Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday, August 8th. Finally, Oppenheimer dropped their price objective on Corbus Pharmaceuticals from $52.00 to $48.00 and set an "outperform" rating on the stock in a report on Friday, August 7th.

Insider Buying and Selling at Corbus Pharmaceuticals

• Corbus Pharmaceuticals NASDAQ: CRBP Gives a Bold Buy Signal

In other Corbus Pharmaceuticals news, CFO Sean Moran sold 12,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $10.08, for a total value of $120,960.00. Following the completion of the sale, the chief financial officer directly owned 84,694 shares of the company's stock, valued at $853,715.52. The trade was a 12.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Yuval Cohen sold 17,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $10.08, for a total transaction of $171,360.00. Following the completion of the sale, the chief executive officer directly owned 157,316 shares of the company's stock, valued at $1,585,745.28. This represents a 9.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 31,000 shares of company stock worth $308,000 over the last ninety days. 3.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of CRBP. Orbimed Advisors LLC boosted its holdings in Corbus Pharmaceuticals by 8.8% in the first quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company's stock worth $16,313,000 after purchasing an additional 140,000 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Corbus Pharmaceuticals by 76.6% during the first quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company's stock worth $1,281,000 after buying an additional 59,248 shares during the last quarter. Exome Asset Management LLC raised its holdings in Corbus Pharmaceuticals by 67.8% during the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company's stock valued at $2,199,000 after buying an additional 94,593 shares in the last quarter. Doliver Advisors LP bought a new position in Corbus Pharmaceuticals during the third quarter valued at about $518,000. Finally, Engineers Gate Manager LP raised its holdings in Corbus Pharmaceuticals by 109.9% during the second quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company's stock valued at $280,000 after buying an additional 15,600 shares in the last quarter. Institutional investors and hedge funds own 64.64% of the company's stock.

Corbus Pharmaceuticals Trading Down 1.9%

Shares of NASDAQ:CRBP opened at $4.05 on Friday. Corbus Pharmaceuticals has a 1 year low of $3.93 and a 1 year high of $18.11. The business has a fifty day simple moving average of $7.79 and a 200 day simple moving average of $8.82. The firm has a market cap of $75.61 million, a price-to-earnings ratio of -0.65 and a beta of 2.63.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.55). On average, sell-side analysts forecast that Corbus Pharmaceuticals will post -5.62 EPS for the current year.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company's research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease.

Corbus' oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.